



bioMérieux receives CE marking for VIDAS[®] 3, the new generation of VIDAS[®]

Marcy l'Étoile, France, June 20, 2013 — bioMérieux, a world leader in the field of *in vitro* diagnostics, announces that VIDAS[®] 3, the new generation of VIDAS[®], has been granted CE marking. This instrument, which further enriches the offering of the VIDAS immunoassay product range, VIDAS and mini VIDAS[®], is now commercially available in Europe and the countries that recognize the CE marking.

VIDAS 3 features enhanced automation, in particular with a pre-analytical section, improved traceability and new software capabilities, as well as a quality control program in compliance with laboratory certification standards. Designed with the help of 1,500 immunoassay laboratories, this new-generation instrument has received an extremely enthusiastic reception by biologists. At congresses where VIDAS 3 has been presented, nearly 200 intentions to purchase the instrument have already been received.

VIDAS 3 reinforces the ease of use that has made the VIDAS range so popular. Thanks to its design, tests can be performed on demand, individually or in series, 24 hours a day and seven days a week. As a result, it is perfectly suited to centralized as well as satellite laboratories, bringing both versatility and reliability to healthcare professionals who are able to optimize their workflows and guarantee the quality of biological testing.

VIDAS 3 uses the same reagents as the other instruments in the VIDAS range. With 99 clinical parameters, the very broad menu of tests allows clinicians to provide diagnosis, monitoring and prognosis for a number of diseases, particularly in the field of infectious diseases and emergency testing. VIDAS 3 is especially well adapted to high medical-value tests, such as VIDAS[®] B.R.A.H.M.S PCT for the measurement of procalcitonin levels, used in emergency settings as a marker of severe bacterial infections.

“Thanks to the VIDAS 3 CE marking, we are now able to provide biologists with an instrument that combines innovative technology and over 20 years of expertise acquired with the previous generations of our immunoassay platforms, VIDAS and mini VIDAS,” said François Lacoste, Corporate Vice President, bioMérieux Immunoassay Unit. “With the launch of VIDAS 3, today bioMérieux expresses its medical vision by developing new solutions to improve people’s health. With this in mind, we will continue to seek regulatory approval in other countries, particularly the United States and China. Our ambition is to commercialize VIDAS 3 worldwide, so that this innovation will be available to as many laboratories as possible.”

With over 27,000 instruments used by clinical laboratory professionals, VIDAS has the largest installed base of automated immunoassay systems in the world.* The VIDAS range makes it possible to meet demand in mature markets for small test series, such as high medical-value, specialty and confirmation tests, while offering the flexibility, reliability and ease of use that are especially well-adapted to needs in emerging countries. VIDAS 3 represents an important step in the continuous development of the VIDAS range worldwide.

* CAP Today, July 2012

About bioMérieux

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2012, revenues reached €1,570 million with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).
Corporate website: www.biomerieux.com. Investor website: www.biomerieux-finance.com.

Contacts

Investor Relations

bioMérieux

Isabelle Tongio

Tel.: + 33 4 78 87 22 37

investor.relations@biomerieux.com

Media Relations

bioMérieux

Aurore Sergeant

Tel: + 33 4 78 87 51 97

media@biomerieux.com

Image Sept

Laurence Heilbronn

Tel: + 33 1 53 70 74 64

lheilbronn@image7.fr

Claire Doligez

Tel: + 33 1 53 70 74 48

cdoligez@image7.fr